Table 5.
Baseline demographics, disease characteristics, treatment details, and TARGET-IBD activity for the year-one study cohort by site of enrollment
| Community (n = 503) | Academic (n = 494) | P | |
|---|---|---|---|
| Age at study entry (years) | |||
| Median (n) | 49 (503) | 40 (489) | <0.0001 |
| Q1–Q3 (IQR) | 34–63 (29) | 30–55 (25) | |
| Female sex, n (%) | 273 (54.3) | 272 (55.1) | 0.8032 |
| Race, n (%) | |||
| White | 435 (90.8) | 397 (82.4) | 0.0006 |
| Black | 28 (5.8) | 58 (12.0) | |
| Other | 16 (3.3) | 27 (5.6) | |
| Not available | 24 | 12 | |
| BMI (kg/m2) | |||
| Median (n) | 27 (498) | 26 (456) | 0.1748 |
| Q1–Q3 (IQR) | 23–31 (8) | 22–31 (9) | |
| Current smoker, n (%) | 49 (10.1) | 33 (7.0) | 0.0840 |
| Not available | 20 | 23 | |
| Disease duration (years) | |||
| Median (n) | 8 (404) | 12 (473) | <0.0001 |
| Q1–Q3 (IQR) | 3–16 (13) | 6–21 (15) | |
| CD location, n (%) | |||
| Colon | 57 (22.7) | 57 (17.6) | 0.2953 |
| Ileocolonic | 143 (57.0) | 193 (59.6) | |
| Ileum | 51 (20.3) | 74 (22.8) | |
| Not available | 15 | 9 | |
| Upper GI tract disease, n (%) | 33 (15.4) | 62 (22.9) | 0.0401 |
| Not available | 52 | 62 | |
| Perianal disease, n (%) | 1 (27.0) | 93 (33.5) | 0.1176 |
| Not available | 40 | 55 | |
| CD behavior, n (%) | |||
| Inflammatory | 126 (53.2) | 115 (37.5) | 0.0009 |
| Stricturing | 51 (21.5) | 98 (31.9) | |
| Penetrating | 60 (25.3) | 94 (30.6) | |
| Not available | 29 | 26 | |
| UC extent, n (%) | |||
| Extensive | 103 (47.9) | 73 (50.0) | 0.9255 |
| Left-sided | 84 (39.1) | 55 (37.7) | |
| Proctitis | 28 (13.0) | 18 (12.3) | |
| Not available | 19 | 8 | |
| Prior biologics, n (%) | |||
| Anti-TNF | 71 (14.1) | 164 (33.2) | <0.0001 |
| Anti-integrin* | 2 (0.4) | 14 (2.8) | 0.0022 |
| Ustekinumab | 0 (0.0) | 4 (0.8) | 0.0433 |
| Medications during study, n (%)† | |||
| 5-ASA | 305 (60.6) | 246 (49.8) | 0.0006 |
| IM‡ | 149 (29.6) | 257 (52.0) | <0.0001 |
| Steroids§ | 284 (56.5) | 284 (57.5) | 0.7430 |
| Anti-TNF | 254 (50.5) | 285 (57.7) | 0.0227 |
| Vedolizumab | 73 (14.5) | 82 (16.6) | 0.3636 |
| Ustekinumab | 12 (2.4) | 49 (9.9) | <0.0001 |
| Tofacitinib | 0 (0.0) | 1 (0.2) | 0.3129 |
| Healthcare encounter count during study, n† | |||
| Endoscopy | 942 | 1204 | |
| Imaging | 389 | 605 | |
| IBD surgery during study, n (%) | 111 (22.1) | 149 (30.2) | 0.0036 |
| At least 1 PRO completed, n (%) | 248 (49.3) | 314 (63.6) | <0.0001 |
| Participation ongoing (%) | 491 (97.6) | 490 (99.2) | 0.0478 |
*Natalizumab or vedolizumab.
†Includes both the 3-year retrospective period as well as prospective data collection.
‡Includes azathioprine, mercaptopurine, or methotrexate.
§Includes prednisone, hydrocortisone, methylprednisolone, and budesonide.